H. Lundbeck A/S

CPSE:HLUN B Stock Report

Market Cap: DKK 43.6b

H. Lundbeck Valuation

Is HLUN B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLUN B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DKK 168.27
Fair Value
72.7% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: HLUN B (DKK46.02) is trading below our estimate of fair value (DKK168.27)

Significantly Below Fair Value: HLUN B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLUN B?

Key metric: As HLUN B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HLUN B. This is calculated by dividing HLUN B's market cap by their current earnings.
What is HLUN B's PE Ratio?
PE Ratio13.1x
EarningsDKK 3.49b
Market CapDKK 43.61b

Price to Earnings Ratio vs Peers

How does HLUN B's PE Ratio compare to its peers?

The above table shows the PE ratio for HLUN B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.9x
ALK B ALK-Abelló
45.1x17.14%DKK 46.1b
NOVO B Novo Nordisk
12.6x6.25%DKK 1.4t
GMAB Genmab
13.1x9.35%DKK 116.2b
BAVA Bavarian Nordic
12.9x-7.83%DKK 18.4b
HLUN B H. Lundbeck
13.1x3.01%DKK 43.6b

Price-To-Earnings vs Peers: HLUN B is good value based on its Price-To-Earnings Ratio (13.1x) compared to the peer average (20.9x).

Price to Earnings Ratio vs Industry

How does HLUN B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
HLUN B 13.1xIndustry Avg. 22.8xNo. of Companies9PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HLUN B is good value based on its Price-To-Earnings Ratio (13.1x) compared to the European Pharmaceuticals industry average (22.8x).

Price to Earnings Ratio vs Fair Ratio

What is HLUN B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLUN B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.1x
Fair PE Ratio15.1x

Price-To-Earnings vs Fair Ratio: HLUN B is good value based on its Price-To-Earnings Ratio (13.1x) compared to the estimated Fair Price-To-Earnings Ratio (15.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLUN B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 46.02
DKK 48.59
+5.59%
17.20%DKK 71.00DKK 41.00n/a11
Oct ’26DKK 46.76
DKK 48.18
+3.04%
17.61%DKK 71.00DKK 39.50n/a11
Sep ’26DKK 40.32
DKK 48.18
+19.50%
17.61%DKK 71.00DKK 39.50n/a11
Aug ’26DKK 33.66
DKK 47.38
+40.75%
18.38%DKK 72.00DKK 38.00n/a12
Jul ’26DKK 36.82
DKK 47.13
+27.99%
18.07%DKK 72.00DKK 38.00n/a12
Jun ’26DKK 36.34
DKK 48.41
+33.21%
17.31%DKK 72.00DKK 39.00n/a11
May ’26DKK 31.56
DKK 49.68
+57.42%
15.68%DKK 70.00DKK 42.50n/a11
Apr ’26DKK 33.56
DKK 50.68
+51.02%
14.86%DKK 70.00DKK 42.50n/a11
Mar ’26DKK 40.00
DKK 51.68
+29.20%
16.90%DKK 71.00DKK 42.50n/a11
Feb ’26DKK 44.08
DKK 51.95
+17.86%
16.37%DKK 71.00DKK 42.50n/a11
Jan ’26DKK 41.32
DKK 50.15
+21.37%
14.83%DKK 69.00DKK 42.50n/a10
Dec ’25DKK 44.00
DKK 50.14
+13.95%
14.04%DKK 69.00DKK 42.50n/a11
Nov ’25DKK 45.18
DKK 48.95
+8.35%
9.18%DKK 57.00DKK 42.50DKK 47.1811
Oct ’25DKK 43.08
DKK 46.29
+7.46%
12.51%DKK 57.00DKK 35.00DKK 46.7612
Sep ’25DKK 47.92
DKK 45.54
-4.96%
11.96%DKK 57.00DKK 35.00DKK 40.3212
Aug ’25DKK 43.52
DKK 40.88
-6.08%
12.46%DKK 55.00DKK 35.00DKK 33.6612
Jul ’25DKK 38.60
DKK 39.96
+3.52%
10.94%DKK 51.00DKK 35.00DKK 36.8212
Jun ’25DKK 37.74
DKK 39.96
+5.88%
10.94%DKK 51.00DKK 35.00DKK 36.3412
May ’25DKK 34.04
DKK 38.71
+13.71%
12.30%DKK 50.00DKK 33.00DKK 31.5612
Apr ’25DKK 33.22
DKK 38.79
+16.77%
12.18%DKK 50.00DKK 33.00DKK 33.5612
Mar ’25DKK 33.06
DKK 38.35
+15.99%
12.50%DKK 50.00DKK 33.00DKK 40.0013
Feb ’25DKK 34.00
DKK 38.27
+12.56%
11.05%DKK 48.00DKK 33.00DKK 44.0813
Jan ’25DKK 32.76
DKK 38.58
+17.76%
10.44%DKK 48.00DKK 33.00DKK 41.3213
Dec ’24DKK 33.06
DKK 38.79
+17.34%
10.78%DKK 48.00DKK 32.00DKK 44.0012
Nov ’24DKK 37.16
DKK 39.05
+5.07%
11.06%DKK 47.00DKK 32.00DKK 45.1811
DKK 48.59
Fair Value
5.3% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/05 17:32
End of Day Share Price 2025/11/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 36 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles PitmanBarclays
Emily FieldBarclays
Rosie TurnerBarclays